NCT02743546 2025-02-03Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in LymphomaJanssen Research & Development, LLCPhase 1 Withdrawn
NCT02388048 2025-01-29Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic LeukemiaGruppo Italiano Malattie EMatologiche dell'AdultoPhase 2 Completed19 enrolled